Author + information
- John V. McMurray, BSc(Hons), MBChB(Hons), MD∗ ()
- ↵∗Address for correspondence:
Institute of Cardiovascular and Medical Sciences, BHF Glasgow Cardiovascular Research Centre, University of Glasgow, 126 University Place, Glasgow, Scotland G12 8TA, United Kingdom
Dr. Levelt and colleagues (1) present an interesting hypothesis linking diabetes to cardiac remodeling through cardiolipotoxicity. Whether vildagliptin reverses cardiolipotoxicity and whether this would lead to left ventricular dilation without a change in left ventricular mass or ejection fraction, as seen in the present trial, is unknown but would certainly be better studied by using cardiac magnetic resonance imaging and spectroscopy.
Please note: Glasgow University received financial support from Novartis for participation in VIVIDD and a number of other clinical trials. Dr. McMurray has reported that he has no relationships relevant to the contents of this paper to disclose.
- 2018 American College of Cardiology Foundation